Michael E. Severino
Net Worth

Last updated:

What is Michael E. Severino net worth?

The estimated net worth of Dr. Michael E. Severino is at least $155,005,485 as of 23 May 2022. He owns shares worth $31,439,082 as insider, has earned $89,246,403 from insider trading and has received compensation worth at least $34,320,000 in AbbVie Inc..

What is the salary of Michael E. Severino?

Dr. Michael E. Severino salary is $4,290,000 per year as Vice Chairman & Pres in AbbVie Inc..

How old is Michael E. Severino?

Dr. Michael E. Severino is 59 years old, born in 1966.

What stocks does Michael E. Severino currently own?

As insider, Dr. Michael E. Severino owns shares in one company:

Company Title Shares Price per share Total value
AbbVie Inc. (ABBV) Vice Chairman & Pres 152,103 $206.7 $31,439,082

What does AbbVie Inc. do?

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

ABBV logo
ABBV
AbbVie Inc.
$206.7

Michael E. Severino insider trading

AbbVie Inc.

Dr. Michael E. Severino has made 18 insider trades between 2017-2022, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 90,679 units of ABBV stock on 4 Nov 2020. As of 23 May 2022 he still owns at least 152,103 units of ABBV stock.

Transaction Date Security Shares Price per share Total value Source
Option
Option (Right to Buy) 46,320 $114.36 $5,297,155
Sale
Common Stock, $0.01 par value 11,605 $151.53 $1,758,506
Option
Option (Right to Buy) 21,739 $105.92 $2,302,595
Option
Common Stock, $0.01 par value 46,320 $114.36 $5,297,155
Option
Common Stock, $0.01 par value 11,742 $93.5 $1,097,877
Sale
Common Stock, $0.01 par value 68,196 $150.79 $10,283,275
Option
Option (Right to Buy) 11,742 $93.5 $1,097,877
Option
Common Stock, $0.01 par value 21,739 $105.92 $2,302,595
Option
Common Stock, $0.01 par value 64,636 $93.5 $6,043,466
Sale
Common Stock, $0.01 par value 54,279 $154.49 $8,385,563
Sale
Common Stock, $0.01 par value 2,100 $155.27 $326,067
Option
Option (Right to Buy) 64,636 $93.5 $6,043,466
Option
Option (Right to Buy) 35,364 $79.02 $2,794,463
Option
Option (Right to Buy) 29,121 $79.02 $2,301,141
Option
Common Stock, $0.01 par value 35,364 $79.02 $2,794,463
Sale
Common Stock, $0.01 par value 43,621 $153.43 $6,692,770
Option
Common Stock, $0.01 par value 70,879 $61.36 $4,349,135
Sale
Common Stock, $0.01 par value 46,273 $154.04 $7,127,893
Sale
Common Stock, $0.01 par value 400 $155.44 $62,176
Option
Common Stock, $0.01 par value 29,121 $79.02 $2,301,141
Sale
Common Stock, $0.01 par value 53,327 $154.8 $8,255,020
Sale
Common Stock, $0.01 par value 22,873 $151.16 $3,457,483
Option
Option (Right to Buy) 25,691 $54.86 $1,409,408
Option
Option (Right to Buy) 33,701 $58.88 $1,984,315
Option
Option (Right to Buy) 29,221 $61.36 $1,793,001
Option
Common Stock, $0.01 par value 70,779 $58.88 $4,167,468
Option
Common Stock, $0.01 par value 29,221 $61.36 $1,793,001
Sale
Common Stock, $0.01 par value 48,591 $152.83 $7,426,163
Sale
Common Stock, $0.01 par value 28,536 $152.24 $4,344,321
Option
Option (Right to Buy) 70,779 $58.88 $4,167,468
Sale
Common Stock, $0.01 par value 31,714 $150.63 $4,777,080
Sale
Common Stock, $0.01 par value 47,215 $149.53 $7,060,059
Option
Common Stock, $0.01 par value 33,701 $58.88 $1,984,315
Sale
Common Stock, $0.01 par value 21,071 $151.42 $3,190,571
Option
Common Stock, $0.01 par value 66,299 $54.86 $3,637,163
Sale
Common Stock, $0.01 par value 90,679 $93.61 $8,488,461
Sale
Common Stock, $0.01 par value 50,000 $97.44 $4,872,100
Sale
Common stock, $0.01 par value 2,643 $117.93 $311,684
Sale
Common stock, $0.01 par value 25,633 $94.69 $2,427,214

AbbVie key executives

AbbVie Inc. executives and other stock owners filed with the SEC: